- Home
- MGYR vs ZNTL Comparison
MGYR vs ZNTL Comparison
Compare MGYR & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGYR
- ZNTL
- Stock Information
- Founded
- MGYR 1922
- ZNTL 2014
- Country
- MGYR United States
- ZNTL United States
- Employees
- MGYR N/A
- ZNTL N/A
- Industry
- MGYR Savings Institutions
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- MGYR Finance
- ZNTL Health Care
- Exchange
- MGYR Nasdaq
- ZNTL Nasdaq
- Market Cap
- MGYR 112.5M
- ZNTL 105.8M
- IPO Year
- MGYR 2006
- ZNTL 2020
- Fundamental
- Price
- MGYR $17.06
- ZNTL $1.79
- Analyst Decision
- MGYR
- ZNTL Buy
- Analyst Count
- MGYR 0
- ZNTL 6
- Target Price
- MGYR N/A
- ZNTL $6.53
- AVG Volume (30 Days)
- MGYR 3.0K
- ZNTL 697.2K
- Earning Date
- MGYR 10-30-2025
- ZNTL 11-11-2025
- Dividend Yield
- MGYR 2.10%
- ZNTL N/A
- EPS Growth
- MGYR 35.01
- ZNTL N/A
- EPS
- MGYR 1.57
- ZNTL N/A
- Revenue
- MGYR $35,533,000.00
- ZNTL $26,865,000.00
- Revenue This Year
- MGYR N/A
- ZNTL N/A
- Revenue Next Year
- MGYR N/A
- ZNTL N/A
- P/E Ratio
- MGYR $10.95
- ZNTL N/A
- Revenue Growth
- MGYR 18.29
- ZNTL N/A
- 52 Week Low
- MGYR $12.10
- ZNTL $1.01
- 52 Week High
- MGYR $19.04
- ZNTL $4.44
- Technical
- Relative Strength Index (RSI)
- MGYR 45.60
- ZNTL 60.98
- Support Level
- MGYR $17.05
- ZNTL $1.54
- Resistance Level
- MGYR $17.27
- ZNTL $1.69
- Average True Range (ATR)
- MGYR 0.14
- ZNTL 0.10
- MACD
- MGYR -0.03
- ZNTL 0.02
- Stochastic Oscillator
- MGYR 2.50
- ZNTL 85.07
About MGYR Magyar Bancorp Inc.
Magyar Bancorp Inc is a mid-tier stock holding company. The Company offers a full array of commercial and retail financial services, including the taking of time, savings and demand deposits; the making of commercial, consumer and home equity loans; and the provision of other financial services. The business consists of getting retail deposits from the general public in the areas surrounding the main office in New Brunswick, New Jersey and branch offices located in Middlesex and Somerset Counties, New Jersey, and investing those deposits, together with funds generated from operations and wholesale funding, in residential mortgage loans, home equity loans, home equity lines of credit, commercial real estate loans, commercial business loans, Small Business Administration loans.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.